Company / Operating Cash Flow
PALVELLA THERAPEUTICS, INC. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$10.8M
FY2024
5-year range
-$59.9M / -$10.8M
FY2020-FY2024
Trend
+20.9%
vs FY2023
Sector context
#81 of 216
Health Care
What the data says
At -$11M, PALVELLA THERAPEUTICS, INC.'s operating cash flow ranks #81 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$60M in FY2022 to $50M in FY2018.
Based on SEC 10-K filings.
-$11M in FY2024.
Improved from -$60M to -$11M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#81 of 216 in Health CareTop 37% of 216This company -$10.8M Sector average $659.0M
▼
-101.6% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow increased 20.9% year-over-year.
- Ranks #81 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$10.8M | +20.9% |
| FY2023 | -$13.7M | +77.1% |
| FY2022 | -$59.9M | -30.6% |
| FY2021 | -$45.9M | +12.5% |
| FY2020 | -$52.5M | +0.0% |
| FY2019 | -$52.5M | -205.5% |
| FY2018 | $49.8M | +445.8% |
| FY2017 | -$14.4M | +0.0% |
| FY2016 | -$14.4M | -13.2% |
| FY2015 | -$12.7M | -82747.4% |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026